News & Updates

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

The use of antioxidant supplements in men seeking fertility care does not appear to increase the chances of conceiving for their female partners, as shown in the multicentre SUMMER trial.

A recent study has shown infliximab’s superiority over adalimumab in the treatment of bio-naïve patients with fistulizing Crohn’s disease (FCD). However, there is no therapeutic difference seen in bio-exposed FCD.

Treatment with the novel cannabinoid receptor 1 (CB1R) inverse agonist monlunabant appears to yield significant and clinically meaningful weight loss in adults with obesity and metabolic syndrome, according to a phase IIa trial.

Compared with intravenous (IV) or oral glucocorticoids (GCs), the use of teprotumumab results in lower risks of mortality and cardiovascular, renal, and infectious outcomes in patients with thyroid eye disease (TED), suggests a study.

Treatment with enoxaparin and nadroparin may speed up wound healing after an operation, reports a study. On the other hand, phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) may delay recuperation.

Women with prenatal exposure to selective serotonin and serotonin-norepinephrine reuptake inhibitors appear to be at increased risk of postpartum haemorrhage, according to a study.

Combination therapy with ezetimibe plus atorvastatin appears to better protect against ischaemic stroke recurrence compared with atorvastatin monotherapy, according to a study.